Aytu BioPharma, Inc.
AYTU
Positions held
Your positionsAYTU isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $22.28M | Enterprise value | $14.07M | Trailing P/E | — | Forward P/E | 13.23 |
| PEG | — | Price / book | 0.62 | Beta | 0.18 | Dividend yield | 0.00% |
| Revenue growth | 6.4% | Earnings growth | — | Gross margin | 64.0% | Operating margin | -4.8% |
| Profit margin | -24.8% | ROE | -52.6% | ROA | -4.5% | Debt / equity | 0.51 |
| Current ratio | 1.13 | Free cash flow | $5.60M | Analyst recommendation | strong_buy | Mean target | $9.67 |
| 52w high | $3.07 | 52w low | $1.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $16.1M | $12.4M | $15.2M | $13.9M | $15.1M | — |
| Op margin | -4.8% | -32.7% | -13.0% | -10.8% | 4.2% | — |
| Net income | -$0.0M | -$5.6M | -$10.6M | $2.0M | -$19.8M | — |
| Gross margin | 64.6% | 61.2% | 63.5% | 66.1% | 67.8% | — |
| Gross profit | $10.4M | $7.6M | $9.6M | $9.2M | $10.3M | — |
| Operating income | -$0.8M | -$4.1M | -$2.0M | -$1.5M | $0.6M | — |
- Revenue +30% vs prior quarter ($16M vs $12M).
- Gross margin 64.6% (was 61.2% prior quarter).
- Operating margin expanded to -4.8%.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $57.6M | $66.4M | $65.2M | $107M | — |
| Op margin | -14.4% | 3.8% | 0.9% | -11.5% | — |
| Net income | -$14.3M | -$13.6M | -$15.8M | -$17.1M | — |
| Gross margin | 64.0% | 69.0% | 75.3% | 62.0% | — |
| Gross profit | $36.8M | $45.8M | $49.1M | $66.6M | — |
| Operating income | -$8.3M | $2.5M | $0.6M | -$12.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
2026-09-23 · Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary
2026-09-23 · Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ...
2026-09-22 · Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
2026-09-22 · Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
2026-09-14 · HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates
2026-07-20 · New Strong Sell Stocks for July 20th
2026-07-16 · New Strong Sell Stocks for July 16th
Price (daily)
Full chart · RSI · MACD · patterns